ViroMed Co., Ltd. is a leading biotechnology company with a mission to discover and develop innovative biopharmaceuticals for human diseases. ViroMed’s numerous achievements since its inception demonstrate that it is one of the most scientifically advanced R&D companies in today’s global biopharmaceutical industry. The company has differentiated itself from competitors with its core technology and seasoned management. ViroMed is headquartered in Seoul, Korea with US presence in Atlanta. The company has assembled a diverse pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with multiple clinical studies ongoing in the US, Korea, and China. ViroMed is publicly ViroMed is publicly listed on KOSDAQ (084990).